Cluster of Differentiation 47 (CD47)

Overview

CD47 is a cell-surface protein best known as a key innate immune checkpoint and a prominent “don’t eat me” signal. By engaging signal regulatory protein alpha (SIRPα) on myeloid cells, CD47 helps suppress phagocytosis and contributes to immune evasion. This function is especially relevant in cancer, where many tumors overexpress CD47 to reduce recognition and clearance by macrophages and other phagocytic cells.

Beyond its role in tumor biology, CD47 is also being explored as a target for immunomodulation in transplantation and regenerative medicine. Recent work has used CD47 blockade or CD47 engineering to alter local immune responses, enhance antitumor immunity, and improve graft survival. In these settings, CD47 is often studied alongside other immune pathways such as PD-L1, Fcγ receptors, and macrophage-mediated phagocytosis, reflecting its central position in checkpoint inhibitor.

Recent Publications Summary

Recent studies have continued to position CD47 as a central innate immune checkpoint and therapeutic target across cancer, transplantation, and inflammatory disease models. In breast cancer, CD47 was examined as part of the THBS1-CD47 axis linking endothelial and tumor-cell communication; Axitinib was reported to disrupt this signaling and, despite inhibiting tumor growth, to increase stemness and promote vasculogenic mimicry in triple-negative breast cancer models 42435251Jul. In pancreatic cancer, a biochemical strategy aimed at blocking CD47 maturation in the endoplasmic reticulum used reengineered iodine-131-loaded nanoparticles to reduce CD47 surface expression and enhance tumor antigen presentation, producing marked tumor inhibition and survival benefit in mice 42015503Apr. CD47 was also incorporated into a ratio-tunable dual-peptide nanoplatform with PD-L1 targeting and ultrasound-activated sonodynamic therapy, where lysosomal degradation of CD47 and PD-L1 was used to enhance dendritic cell maturation and antitumor immunity 41979280Apr.

Several publications focused on CD47 blockade to reprogram the tumor microenvironment and improve phagocytic immunity. CDK4/6 inhibition was reported to potentiate anti-CD47 therapy by shifting tumor-associated macrophages toward an M1 phenotype, increasing macrophage phagocytosis, and enhancing effector T cell responses in preclinical breast cancer models 42307815Jun. A biomimetic nanovesicle platform co-displaying StcE and CD47 nanobodies was designed to degrade the tumor glycocalyx and improve CD47 binding on tumor cells, thereby strengthening antitumor immune responses in colorectal and breast cancer models 42133749May. Similarly, an in situ self-assembled glycopeptide was reported to target CD206 and CD47, repolarize M2-like macrophages to M1-like macrophages, and promote antigen presentation and T cell-mediated immunity 42105865May. In melanoma, a metal-organic framework nanodrug combined anti-CD47 antibodies with the STING agonist diABZI to block the CD47-SIRPα interaction and enhance chemodynamic and immune effects 41723989Feb. Additional CD47-directed approaches included an oncolytic vaccinia virus encoding an anti-CD47 nanobody in multiple myeloma, which increased macrophage phagocytosis, remodeled the tumor microenvironment, and synergized with bortezomib 41858619Mar, as well as aGD2-SIRPα fusion antibodies for neuroblastoma that locally restricted CD47 blockade to GD2-positive tumor cells 41054394Oct.

Beyond oncology, CD47 was studied in immune regulation, transplantation, and inflammatory disease. LAV-BPIFB4 was reported to reshape platelet immune features through CD47 upregulation, with centenarians and LAV-BPIFB4 carriers showing increased CD47-positive reticulated platelets and platelets suppressing monocyte activation and inflammatory cytokine production in a CD47-dependent manner 42345378Jun. In allogeneic islet transplantation, transient co-engineering of islets with thrombomodulin and CD47 produced sustained graft survival without chronic immunosuppression and generated a localized tolerogenic immune environment 41842939Mar. In severe acute pancreatitis, kaempferol was reported to functionally reprogram CD47 signaling to promote cytoprotection and attenuate oxeiptosis in pancreatic acinar cells, using CD47-manipulated cell and mouse models together with biophysical validation of direct target engagement 42184499May. CD47-targeted therapy was also explored clinically and in combination settings, including an open-label phase I trial of LM-101, an anti-SIRPα antibody that blocks the CD47-SIRPα interaction in relapsed/refractory lymphoma and advanced head and neck cancer 41910591Mar, and a study of imiquimod to enhance anti-tumor effects of CD47 targeting in oral squamous cell carcinoma 41998354Apr.

What Changes, What Holds

1. CD47 is being used as a lever to reshape tumor signaling and antigen presentation, not just as a phagocytosis checkpoint
REINFORCES These studies stay within the established account of CD47 as an immune-evasion target, but they broaden the therapeutic logic: reducing CD47 surface availability or disrupting CD47-linked signaling is being paired with strategies meant to improve antigen presentation and antitumor immunity. The main takeaway is not a new biological role, but a stronger case that CD47-directed interventions may need to be judged for downstream effects on tumor plasticity and immune activation 42015503Apr41979280Apr.

2. CD47 blockade is increasingly being combined with microenvironmental reprogramming to amplify phagocytic immunity
REINFORCES This work sharpens the baseline view that CD47 suppresses macrophage-mediated clearance by showing that its therapeutic value may depend on the surrounding tumor ecosystem, including macrophage state, glycocalyx barriers, and complementary innate immune pathways. It does not overturn the “don’t eat me” model; instead, it argues that CD47 targeting may work best as part of multi-pronged immune remodeling rather than as a stand-alone brake release 42307815Jun42133749May.

3. CD47 now appears relevant to platelet immunobiology, graft tolerance, and inflammatory cell death, but these roles sit beside rather than against its checkpoint function
NEW DIRECTION The Overview covers cancer, transplantation, and regenerative immunomodulation, but not platelet-mediated immune regulation or pancreatitis-associated cytoprotection. These findings extend CD47 into new physiological and disease contexts without displacing the established SIRPα-dependent checkpoint model. The transplantation result is consistent with prior graft-survival interest, while the platelet and pancreatitis data suggest CD47 may also be a modifiable node in systemic inflammation and tissue protection 42345378Jun41842939Mar42184499May.